Psoriatic Arthritis

Ustekinumab Approved by the FDA for Pediatric Patients with Psoriatic Arthritis
August 01, 2022

Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ustekinumab as a new treatment option for patients aged 6 years or older with active psoriatic arthritis.

Key Pearls on Innovative Treatments in PsA
June 26, 2022

Arthur Kavanaugh, MD, a professor of medicine and director of the Center for Innovative Therapy (CIT) at UC San Diego in California, gives his thoughts on the treatments for psoriatic arthritis, the comorbidities that have to be considered, and more.

What Might the Future Hold for Patients with PsA
June 25, 2022

Arthur Kavanaugh, MD, a professor of medicine and director of the Center for Innovative Therapy (CIT) at UC San Diego in California, gives his thoughts on the future of psoriatic arthritis.

A Potpourri of Complex Medical Terminology
June 17, 2022

At the SDPA 2022 Annual Summer Dermatology Conference, a session on both common and rare dermatological disorders.

LEO Pharma Presents New Tralokinumab-ldrm Data
February 09, 2022

Tralokinumab-ldrm (Adbry; LEO Pharma) showed improvement in itch, sleep, anxiety, depression, and overall quality of life data for adolescent AD patients in newly released study data.

Risankizumab Receives FDA Approval for Active Psoriatic Arthritis
January 28, 2022

AbbVie announced the FDA approval to their IL-23 inhibitor risankizumab-rzaa (Skyrizi) for treatment of active psoriatic arthritis (PsA) in adult patients based on the results of the KEEPsAKE-1 and KEEPsAKE-2 trials.

Secukinumab Receives FDA Approval for Pediatric Patients with PsA
December 23, 2021

Secukinumab is the only biologic treatment in the US that’s approved by the FDA for pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).

Study: Risk of Psoriasis Related to BMI
December 21, 2021

A study in the Journal of the American Academy of Dermatology examined the incidence of psoriasis according to body mass index.

Apremilast Use During COVID-19
December 21, 2021

A recent study investigated apremilast use for psoriasis during COVID-19 infection.

Upadacitinib Receives FDA Approval for Active Psoriatic Arthritis
December 15, 2021

The FDA approves upadacitinib (Rinvoq; AbbVie) for the treatment of adult patients with active psoriatic arthritis.